

Fluorescent Imaging Agent

Caution: For Laboratory Use. A product for research purposes only.

IntegriSense™ 645

Product Number: NEV10640

DESCRIPTION: *IntegriSense*™ 645 is a targeted fluorescent imaging agent comprising a potent, selective non-peptide small molecule integrin $\alpha_v\beta_3$ antagonist and a near-infrared (NIR) fluorochrome. This agent has been developed to enable in vivo visualization and quantification of integrin expressed in tumor cells as well as in neovasculature, to monitor tumor growth, tumor angiogenesis, and treatment efficacy. Half-life of *IntegriSense* 645 in tissue is approximately 2 days

MATERIAL:

CONTENTS: Each vial contains 24 nmol of *IntegriSense* 645 as a 20 μ M solution in 1 x PBS which has been filtered through a 0.2 μ m filter prior to filling. The solution is ready for injection. The packaged material provides sufficient reagent for imaging approximately 10 mice (weighing ~25 grams each) when using the recommended dose of 2 nmol (100 μ L) of *IntegriSense* 645 per mouse.

PROPERTIES: The physical characteristics of *IntegriSense* 645 can be found in **Table 1** and **Figure 1**.

STORAGE & HANDLING:

- Upon receipt, *IntegriSense* 645 should be **IMMEDIATELY STORED AT 2-8 °C AND PROTECTED FROM LIGHT**.
- When stored and handled properly, *IntegriSense* 645 is stable for up to three months as a PBS solution at 2-8 °C and protected from light from the date of shipment.

IN VIVO IMAGING AND APPLICATIONS:

- The generally recommended procedure for *in vivo* imaging with *IntegriSense* 645 is administration via intravenous injection and imaging **6-24 hours post injection**.
- Imaging may be performed as early as 3 hours with some reduction in target signal/noise.
- *IntegriSense* 645 will clear from tissues after approximately 6-7 days. Repeat injection and imaging may be performed every 3 days for longitudinal studies. It is recommended that a pre-injection baseline image be taken prior to reinjection and imaging, unless injections are performed every 7 days.
- *IntegriSense* 645 enables imaging of tumors and neovasculature in a range of oncology applications.

Table 1. *IntegriSense* 645 Characteristics

Property	Specification
MW	~ 1250 g mol ⁻¹
Fluorescence ¹	
• Excitation	649 nm
• Emission	666 nm
Absorbance ¹	649 nm
Purity ²	>90%
Appearance	Clear blue solution

1. Absorbance and fluorescence maxima of *IntegriSense* 645 in 1x PBS.

2. As determined by RP-HPLC and measuring absorbance at 645 nm.




Figure 1. Normalized absorbance (blue) and fluorescence emission (red) spectra of *IntegriSense* 645 in 1x PBS.

NOTES:

- *PerkinElmer's IntegriSense 645* is intended for research purposes only and is not for human use. It must be used by or directly under the supervision of a technically qualified individual experienced in handling potentially hazardous materials. Please read the Material Safety Data Sheet (MSDS) provided for this product.
- Several of *PerkinElmer's* products and product applications are covered by U.S. and foreign patents and patents pending. Our products are not available for resale or other commercial uses without a specific agreement with *PerkinElmer*.

PerkinElmer, Inc.
549 Albany Street
Boston, MA 02118 USA
P: (800) 762-4000 or (+1) 203-925-4602
www.perkinelmer.com/nenradiochemicals

For a complete listing of our global offices, visit www.perkinelmer.com/ContactUs

Copyright ©2010, PerkinElmer, Inc. All rights reserved. PerkinElmer® is a registered trademark of PerkinElmer, Inc.
All other trademarks are the property of their respective owners.

